|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
These observations further support the use of drug combinations for the optimal management of TP53-M CLL patients.
|
30338509 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
These data suggest that the percentage of cells with del(17p), the size of the del(17p) subclone, CLL International Prognostic Index, and CK should be considered to build refined prognostication models for patients with TP53 disruption.
|
30350431 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Taking p53 abnormality as the cut-off value criteria, low expression levels of miR-34a (cut-off value 4.65, P = 0.02) and miR-29b (cut-off value 4.71, P = 0.009) hinted at a poor treatment-free survival (TFS) prognosis for all CLL patients.
|
31425738 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
We report a customized gene panel assay based on multiplex long-PCR followed by third generation sequencing on nanopore technology (MinION), designed to analyze five frequently mutated genes in chronic lymphocytic leukemia (CLL): TP53, NOTCH1, BIRC3, SF3B1 and MYD88.
|
30087429 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
In the TP53 cohort, the estimated 5-year progression-free survival (PFS) was 74.4% in TN-CLL compared with 19.4% in RR-CLL (<i>P</i> = .0002), and overall survival (OS) was 85.3% vs 53.7%, respectively (<i>P</i> = .023).
|
29483101 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Assessment of somatic and germline TP53 alterations has now reached the clinic and is required in several circumstances such as the identification of the most effective cancer therapy for patients with chronic lymphocytic leukemia (CLL).
|
29696732 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Ibrutinib was FDA-approved for the upfront treatment of CLL in 2016 after being studied in older patients and those with 17p deletions or TP53 mutations.
|
29480432 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
NDRG2 mRNA levels might be a useful prognostic variable for patients of CLL and up-regulating NDRG2 transcription may be a therapy approach in CLL without p53 aberrations.
|
30348117 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Evidence came from three single-arm trials in CLL patients with or without 17p deletion [del(17p])/TP53 chromosomal abnormalities.
|
29222670 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
The patient treated with ICI is in sustained remission of her melanoma after 23 cycles of therapy while her TP53 disrupted CLL continues to respond to ibrutinib therapy.
|
30005183 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Overall, 69 somatic mutations in 29 CLL driver genes were detected among 45 subjects (46%), with the most frequently mutated genes being TP53 (8·2%), NOTCH1 (8·2%) and ATM (5·1%).
|
29687880 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
TP53 pathway defects contributed to therapy resistance and adverse clinical outcome in chronic lymphocytic leukemia (CLL), which represents an unmet clinical need with few therapeutic options.
|
29895969 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.
|
29467486 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A panel of wild-type and mutant p53 cancer cell lines of different tissues, including pancreas, breast, skin, and lung were used, as well as chronic lymphocytic leukemia (CLL) patients with different TP53 gene status.
|
30318520 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
Further progress in targeted therapy and judicious use of chemotherapy, monoclonal antibodies, and reduced-intensity allogeneic transplantation will provide patients with CLL in general, and those with TP53 abnormalities in particular, with a better prognosis.
|
30315344 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
Among different biomarkers (e.g., CD38, chromosomes abnormalities, ZAP-70, TP53, and microRNA [miRNA]), miRNAs have appeared as new diagnostic and therapeutic biomarkers in patients with the CLL disease.
|
28084621 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
In addition to clinical prognostic features such lactate dehydrogenase level, platelet count, and performance status, important predictors of poor outcome in RT are TP53 disruption and clonal relationship of DLBCL to underlying CLL.
|
29063177 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
|
30423551 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Richter syndrome might be both clonally related or unrelated to the underlying CLL and often showed mutations of the TP53 and NOTCH1 genes.
|
29484684 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We carried out a mutation analysis of TP53 gene in 72 patients with CLL.
|
28476805 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
This review discusses: (i) disease-related (TP53 defects, immunoglobulin gene mutations), therapy-related (duration of remission), and patient-related (age, comorbidities) biomarkers that can be used in the clinical practice to inform CLL treatment decision either at the time of first line therapy and disease relapse; and (ii) the need of new biomarkers to re-define high-risk CLL because of the questioning by novel agents of historical prognostic factors.
|
27808579 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.
|
28418900 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Excepting NOTCH1, TP53 and XPO1, which showed a lower incidence in MBL, genes were mutated with a similar prevalence to CLL, indicating the early origin of most driver mutations in the MBL/CLL continuum.
|
27469216 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
|
28427204 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
This review provides an overview of current treatment options for 17p-deleted/ TP53-mutated CLL, including those compounds that are already approved by the US Food and Drug Administration or are under advanced clinical investigation.
|
28605616 |
2017 |